×
Back to Agenda
Progressing the Development of Disease-Modifying Medicines for the Prevention of Paediatric-Onset Prevalent Chronic Diseases
Session Chair(s)
Ane Sofie Böhm Nielsen, MA, MPA
VP, Regulatory Policy & Intelligence, Novo Nordisk A/S, Denmark
This session will focus on the importance of early availability of novel medicines for children and adolescents facing early onset of serious chronic diseases. The panel will discuss how to progress the clinical development with the aim to bring us a step closer to providing such transformative medicines to children earlier than typically today.
Speaker(s)
Cécile Mathilde Ollivier, MS
Vice President, Global Affairs - Managing Director, Europe, Critical Path Institute, Netherlands
Kyle Jacques Rose
Patient, Patient, United States
Veerle Vanhuyse
, Communication Representative INNODIA, Belgium
Have an account?